Skip to main content

Table 1 Items included in the questionnaire about “General approach to polysensitized subjects” (1A) and results (1B)

From: Diagnosis and allergen immunotherapy treatment of polysensitised patients with respiratory allergy in Spain: an Allergists’ Consensus

1A) 1B)     
Items Mean Median % Panellists against IQ Result
Diagnostic approach to a patient with suspected respiratory allergy
1- Skin-tests are sufficient for the correct aetiologic diagnosis of patients with respiratory allergy 3.08 3 32.26 2 D
2- The size of the wheal is useful in the clinically relevant allergen identification 3.75 3 35 2.5 NC
3- A positive skin-test indicates the clinical relevance of the allergenic source 2.11 2 9.68 1.5 D
4- The specific IgE determination and quantification help us to establish the clinical relevance of an allergenic source 6.22 7 28.33 1 A
5- Molecular diagnosis serves to differentiate primary sensitisation from cross-reactivity 7.84 8 6.45 1 A
6- In molecular diagnostic tests, a cut-off that allows us to differentiate relevant allergens does not exist 6.97 7 27.42 2 A
7- The patient diagnostic approach must be similar, independent of whether respiratory symptoms are persistent or intermittent 6.92 8 25.81 3 A
8- The directed medical history and symptoms-exposure schedule allows us to identify the responsible allergenic source of the patient’s clinic in some cases 7 7 11.67 0 A
9- Organ-specific provocation tests are not useful in daily clinical practice due to their difficult interpretation and because they are time consuming 7.1 8 16.67 1 A
10a- The polysensitised patient is one who presents sensitisation to various allergenic sources 7.47 8 11.67 2 A
10b- The polyallergic patient is one who presents sensitisation with demonstrated clinical relevance 7.90 8 8.33 1 A
11- The aerobiological information should include the allergenic load in the environment 7.42 8 14.52 1 A
Determinant criteria in immunotherapy prescription
12- Before immunotherapy prescription to a polysensitised patient, an organ-specific provocation with all suspected relevant allergens must be conducted 2.4 2 17.74 2 D
13- Assessment of the intensity of symptoms and medication consumption in relation to allergenic exposure should be habitual practice in immunotherapy prescription 8.23 8 1.61 1 A
14- Immunotherapy should only be used based on clinical studies that follow current guidelines 6.92 7.5 29.03 2.5 A
15-Immunotherapy prescription is advised only if relevant allergen sources are identified 7.22 7 6.67 1 A
Immunotherapy composition
16- Enzymatic activity (proteolysis) over others should not be used 7.6 8 14.52 2 A
17- It is acceptable to include up to two or three allergens in one vaccine if their relevance is identified 6.28 7 28.33 2 A
18- Immunotherapy should include all relevant allergenic sources 3.63 3 25 1 D
19- Safety studies of a given extract are applicable to all extracts from identical allergenic sources 2.31 2 14.52 2 D
20- Efficacy studies of a given extract are assimilable to all extracts from identical allergenic sources 2.55 2 17.74 2 D
21- The extract mixture has a nonspecific positive therapeutic effect despite dosage reduction of included allergens 4.27 5 46.67 2 NC
22- If mixtures of several allergenic sources are used in immunotherapy, it is necessary to ensure the effective concentration of each one in the final composition 7.89 8 6.45 2 A
24- The dose–response studies are conducted with vaccines from one allergenic source so the results cannot be extrapolated to those of mixtures 7.16 8 22.58 1.5 A
  1. A = Agreement; D = Disagreement; NC = No Consensus; IQ = Interquartile range.
  2. % panellists = percentage of panellists out of the median region.